Literature DB >> 3488907

Heterogeneity of responsiveness of chronic lymphocytic leukemic B cells to B cell growth factor or interleukin 2.

C Hivroz, C Grillot-Courvalin, J C Brouet, M Seligmann.   

Abstract

We compared the proliferative responses of purified human leukemic B cells from 12 cases of chronic lymphocytic leukemia to highly purified B cell growth factor (BCGF) and recombinant interleukin 2 (rIL 2) spontaneously, and in a coactivation assay using anti-mu monoclonal antibodies. Heterogeneity of response to one or the other lymphokine was observed from case to case. Spontaneous responses were observed to BCGF in one case, to rIL 2 in 3 cases and to both lymphokines in one other case. Costimulation with anti-mu monoclonal antibody induced a proliferative response to BCGF in 3 additional cases and to rIL 2 in 4 cases. Interestingly, cells from BCGF-responsive cases also proliferated in response to rIL 2. The leukemic B cells from 4 chronic lymphocytic leukemia patients were unresponsive. Cells from 5 cases expressed IL 2 receptors, although rIL 2 induced a direct proliferative response in only 3 of these cases. Expression of the B cell activation antigen B5 was associated to BCGF responsiveness.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488907     DOI: 10.1002/eji.1830160821

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Response of neoplasms of B cell lineage to the proliferative effects of B cell growth factor and the phorbol ester TPA.

Authors:  M C Kinney; R D Collins; J Whitlock; J B Cousar; L B Vogler
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

2.  Lymphoma cell culture under serum-free conditions.

Authors:  Y C Dai; X H Wang; N Jamal; H A Messner
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-08       Impact factor: 2.416

3.  Cellular activation without proliferation to B cell growth factor and interleukin 2 in chronic lymphocytic leukaemia B cells stimulated with phorbol ester plus calcium ionophore.

Authors:  P Engel; J Inglés; O de la Calle; T Gallart
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

4.  Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia.

Authors:  Kiyotaka Kawauchi; Toshie Ogasawara; Masako Yasuyama
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

5.  Prolactin-immunoglobulin G complexes from human serum act as costimulatory ligands causing proliferation of malignant B lymphocytes.

Authors:  A M Walker; D W Montgomery; S Saraiya; T W Ho; H S Garewal; J Wilson; L Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

6.  Increased spontaneous secretion of IL-6 from B cells of patients with B chronic lymphatic leukaemia (B-CLL) and autoimmunity.

Authors:  N Lahat; E Aghai; B Maroun; A Kinarty; M Quitt; P Froom
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

7.  Detection and characterization of human high molecular weight B cell growth factor receptors on leukemic B cells in chronic lymphocytic leukemia.

Authors:  F M Uckun; A S Fauci; M Chandan-Langlie; D E Myers; J L Ambrus
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

8.  Effect of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells.

Authors:  T Mainou-Fowler; J A Copplestone; A G Prentice
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

9.  Interleukin 10 (IL-10) upregulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes.

Authors:  A C Fluckiger; P Garrone; I Durand; J P Galizzi; J Banchereau
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

10.  Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells.

Authors:  A C Fluckiger; I Durand; J Banchereau
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.